Brands Names of Lincomycin in Kenya
Lincar-B®, Globe
Lincocin®, Pfizer Upjohn
Lincomycin, Gracure
Lincomycin, Swiss Parenterals (Pvt.) Ltd
Lincozed®, Zawadi Healthcare Ltd
Mechanism of Action:
Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro.
INDICATIONS:
Lincomycin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial associated pseudomembranous colitis, the physician should consider the nature of the infection and the suitability of other alternatives.
Indicated surgical procedures should be performed in conjunction with antibacterial therapy.
The drug may be administered concomitantly with other antimicrobial agents when indicated.
Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Lincomycin and other antibacterial drugs, Lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
CONTRAINDICATIONS:
This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.
DRUG INTERACTIONS
- lincomycin increases effects of Neuromascular Junction Blockers by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- lincomycin, rimabotulinumtoxin B. Either increases effects of the other by pharmacodynamic synergism.Closely monitor for increased neuromuscular blockade.
ADVERSE DRUG REACTIONS
Gastrointestinal disorders
Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort , anal pruritus
Skin and subcutaneous tissue disorders
Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis,dermatitis bullous, dermatitis exfoliative, erythema multiforme , rash, urticaria, pruritus
Infections and infestations
Vaginal infection, pseudomembranous colitis, Clostridium difficile colitis (see Vaginal infection, pseudomembranous colitis, Clostridium diffi cile colitis
Blood and lymphatic system disorders
Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura
Immune system disorders
Anaphylactic reaction , angioedema, serum sickness
Hepatobiliary disorders
Jaundice, liver function test abnormal, transaminases increased
Renal and urinary disorders
Renal impairment, oliguria, proteinuria, azotemia
Cardiac disorders
Cardio-respiratory arrest
Vascular disorders
Hypotension , thrombophlebitis1
Ear and labyrinth disorders
Vertigo, tinnitus
Neurologic disorders
Headache, dizziness, somnolence
General disorders and administration site conditions
Injection site abscess sterile , injection site induration , injection site pain , injection site irritation
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Lincomycin in Kenya
Lincomycin in Kenya
Lincomycin in Kenya
Lincomycin in Kenya
Lincomycin in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: C (Risk not ruled out)
Routes of Administration: IM/IV
Bioavailability: Not Available
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: 5.4 ± 1.0 h after IM or IV administration
Excretion: renal and biliary
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , â„ž-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
| CAS Number | |
|---|---|
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Drug Images
References/ Citation:
- PPB Drugs Retention Register
- Hoeksema, H., et al. “Chemical studies on lincomycin. I. The structure of lincomycin.” Journal of the American Chemical Society 86.19 (1964): 4223-4224.
- Bartlett, John G., Vera L. Sutter, and Sydney M. Finegold. “Treatment of anaerobic infections with lincomycin and clindamycin.” New England Journal of Medicine 287.20 (1972): 1006-1010.